A team at Scripps Research and the Broad Institute of Harvard and MIT has discovered a new method to hone in on new drug targets most likely to impact multiple cancers.
Researchers at Baylor College of Medicine and collaborating institutions developed a kinase inhibitor pulldown assay that can optimally enrich and quantify the small amounts of kinases present in biopsy samples in combination with mass-spectrometry techniques.
